[go: up one dir, main page]

EE05091B1 - Oligosaccharides, process for their preparation and use, and pharmaceutical compositions - Google Patents

Oligosaccharides, process for their preparation and use, and pharmaceutical compositions

Info

Publication number
EE05091B1
EE05091B1 EEP200200208A EEP200200208A EE05091B1 EE 05091 B1 EE05091 B1 EE 05091B1 EE P200200208 A EEP200200208 A EE P200200208A EE P200200208 A EEP200200208 A EE P200200208A EE 05091 B1 EE05091 B1 EE 05091B1
Authority
EE
Estonia
Prior art keywords
oligosaccharides
pharmaceutical compositions
preparation
diastereomers
mixtures
Prior art date
Application number
EEP200200208A
Other languages
Estonian (et)
Inventor
Mourier Pierre
Perrin Elisabeth
Stutzmann Jean-Marie
Viskov Christian
Wahl Florence
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200200208A publication Critical patent/EE200200208A/en
Publication of EE05091B1 publication Critical patent/EE05091B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Materials Engineering (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The invention concerns oligosaccharides of formula (I), their mixtures, their diastereomers, methods for preparing them and pharmaceutical compositions containing them.
EEP200200208A 1999-10-22 2000-10-18 Oligosaccharides, process for their preparation and use, and pharmaceutical compositions EE05091B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9913182A FR2800074B1 (en) 1999-10-22 1999-10-22 NOVEL OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR2000/002897 WO2001029055A2 (en) 1999-10-22 2000-10-18 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same

Publications (2)

Publication Number Publication Date
EE200200208A EE200200208A (en) 2003-06-16
EE05091B1 true EE05091B1 (en) 2008-10-15

Family

ID=9551218

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200208A EE05091B1 (en) 1999-10-22 2000-10-18 Oligosaccharides, process for their preparation and use, and pharmaceutical compositions

Country Status (30)

Country Link
EP (1) EP1226148B1 (en)
JP (1) JP4733329B2 (en)
KR (2) KR100778166B1 (en)
CN (1) CN1241932C (en)
AT (1) ATE534656T1 (en)
AU (1) AU781414B2 (en)
BR (1) BR0014939A (en)
CA (1) CA2388369C (en)
CY (1) CY1112274T1 (en)
CZ (1) CZ303255B6 (en)
DK (1) DK1226148T3 (en)
EA (1) EA004046B1 (en)
EE (1) EE05091B1 (en)
ES (1) ES2376409T3 (en)
FR (1) FR2800074B1 (en)
HR (1) HRP20020330A2 (en)
HU (1) HU229385B1 (en)
IL (2) IL149154A0 (en)
ME (1) MEP9309A (en)
MX (1) MXPA02003945A (en)
NO (1) NO323409B1 (en)
NZ (1) NZ518539A (en)
PL (1) PL204623B1 (en)
PT (1) PT1226148E (en)
RS (1) RS50829B (en)
SK (1) SK287459B6 (en)
TR (1) TR200201102T2 (en)
UA (1) UA72545C2 (en)
WO (1) WO2001029055A2 (en)
ZA (1) ZA200203102B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676048B2 (en) * 2000-07-10 2011-04-27 生化学工業株式会社 Demyelinating disease treatment
CA2431709A1 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
DE10121003A1 (en) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
FR2844808B1 (en) * 2002-09-23 2005-02-25 Aventis Pharma Sa METHOD OF DETERMINING SPECIFIC GROUPS CONSISTING OF HEPARINS OR HEPARINS OF LOW MOLECULAR WEIGHT
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
FR2857971B1 (en) * 2003-07-24 2005-08-26 Aventis Pharma Sa MIXTURES OF HEPARIN DERIVED OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP1580197A1 (en) * 2004-03-24 2005-09-28 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
DE102005017799A1 (en) * 2005-04-18 2006-10-19 Abbott Gmbh & Co. Kg Use of heparin- or heparin derivative to treat illness associated with neurite plasticity or -growth defects, modulates interaction between Nogo receptor and ligands
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
FR2949114B1 (en) * 2009-08-14 2011-08-26 Sanofi Aventis FGF RECEPTOR ACTIVATORY N-ACYLATED OCTASACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2949115B1 (en) * 2009-08-14 2012-11-02 Sanofi Aventis FGF RECEPTOR ACTIVATOR N-SULFATE OLIGOSACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011090948A1 (en) 2010-01-19 2011-07-28 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102864191A (en) * 2011-12-16 2013-01-09 深圳市海普瑞药业股份有限公司 Heparin disaccharide mixture and preparation method and application thereof
CN104910217B (en) * 2015-06-19 2018-04-17 天津红日药业股份有限公司 Reference compound for Fondaparinux sodium quality control
CZ308106B6 (en) * 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
CN110092848A (en) * 2019-05-14 2019-08-06 山东辰龙药业有限公司 A kind of preparation method of Bemiparin sodium
CN119708089A (en) * 2023-09-27 2025-03-28 南开大学 Sulfonated trisaccharide, preparation method and therapeutic application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519987A1 (en) * 1982-01-15 1983-07-22 Choay Sa Uronic acid derivs. - useful as glycoside intermediates or hapten(s)
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2764511B1 (en) * 1997-06-13 2000-09-08 Sanofi Sa COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOSIS AND USE OF A FACTOR XA INHIBITOR ALONE AND / OR IN COMBINATION WITH A PLAQUET ANTIAGGREGANT
JP4166851B2 (en) * 1997-09-29 2008-10-15 生化学工業株式会社 Novel inhibitor of ischemia / reperfusion injury

Also Published As

Publication number Publication date
UA72545C2 (en) 2005-03-15
CA2388369C (en) 2011-02-01
ATE534656T1 (en) 2011-12-15
CY1112274T1 (en) 2015-12-09
KR100872215B1 (en) 2008-12-05
NO20021859D0 (en) 2002-04-19
HU229385B1 (en) 2013-11-28
HRP20020330B1 (en) 2013-01-31
HUP0203821A3 (en) 2003-10-28
HUP0203821A2 (en) 2003-04-28
MXPA02003945A (en) 2002-10-23
SK287459B6 (en) 2010-10-07
IL149154A (en) 2008-04-13
KR20070087263A (en) 2007-08-27
FR2800074A1 (en) 2001-04-27
CN1379781A (en) 2002-11-13
NZ518539A (en) 2004-10-29
CA2388369A1 (en) 2001-04-26
PL363052A1 (en) 2004-11-15
ZA200203102B (en) 2003-09-23
YU29802A (en) 2006-01-16
RS50829B (en) 2010-08-31
EP1226148B1 (en) 2011-11-23
SK5272002A3 (en) 2002-08-06
ES2376409T3 (en) 2012-03-13
WO2001029055A3 (en) 2002-02-14
JP2003512385A (en) 2003-04-02
AU7930200A (en) 2001-04-30
TR200201102T2 (en) 2002-12-23
EA200200479A1 (en) 2002-10-31
EA004046B1 (en) 2003-12-25
KR20020063881A (en) 2002-08-05
HK1050535A1 (en) 2003-06-27
BR0014939A (en) 2002-06-18
PL204623B1 (en) 2010-01-29
KR100778166B1 (en) 2007-11-27
CN1241932C (en) 2006-02-15
NO20021859L (en) 2002-06-13
WO2001029055A2 (en) 2001-04-26
EP1226148A2 (en) 2002-07-31
JP4733329B2 (en) 2011-07-27
CZ20021385A3 (en) 2002-07-17
IL149154A0 (en) 2002-11-10
PT1226148E (en) 2012-01-24
NO323409B1 (en) 2007-04-30
CZ303255B6 (en) 2012-06-27
HRP20020330A2 (en) 2004-04-30
MEP9309A (en) 2011-12-20
DK1226148T3 (en) 2012-03-19
EE200200208A (en) 2003-06-16
FR2800074B1 (en) 2001-12-21
AU781414B2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
EE200200208A (en) Oligosaccharides, process for their preparation and use, and pharmaceutical compositions
DE60112609D1 (en) Pyrazolopyridine
DE60204452D1 (en) [1,5] pyridine derivatives
PL366198A1 (en) Novel compounds
SE9904505D0 (en) Novel compounds
SE9901875D0 (en) Novel compounds
DE60112330D1 (en) Pyrazolopyridinderivate
ATE255589T1 (en) CRYSTALLINE FORM I OF CLARITHROMYCIN
ATE316083T1 (en) ADAMANTANDE DERIVATIVES
DE60001586D1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
SE9804212D0 (en) Compounds
SE9902551D0 (en) Novel compounds
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
MXPA02012426A (en) Novel compounds.
DE60201074D1 (en) Pyrazolopyridinderivate
SE9904128D0 (en) Novel compounds
YU72802A (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
MXPA03010259A (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof.
SE9803107D0 (en) Novel Compunds
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
SE9803277D0 (en) Novel compounds
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20141018